Our Privacy Statment & Cookie Policy

All LSEG websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

The Financial & Risk business of Thomson Reuters is now Refinitiv

All names and marks owned by Thomson Reuters, including "Thomson", "Reuters" and the Kinesis logo are used under license from Thomson Reuters and its affiliated companies.

May 29, 2014

Idea Of The Week: Market Broker ICAP – Wounded Or Poised To Win?

by Steven Carroll.

When counting the casualties of the steady reduction in volatility across many asset classes, the bell tolls for brokers. Their entire business model is predicated on people wanting to trade. With nothing going on in many asset classes – FX volatility, FI volatility and the VIX all showing a steady downward drift – it seems that brokers as well as customers are sitting on their hands. The share performance of U.K.-based broker ICAP plc (IAP.L) reflects this – essentially flat over five years while the (hardly pacesetting) FTSE is up 55%.

Check out the chart below.

Idea A

Source: Thomson Reuters Eikon, StarMine

Anemic forecasts

The sell side has certainly joined the pity party – with large reductions in I/B/E/S forecasts across the income statement – for both the March 2015 and March 2016 fiscal years. Recommendations remain equally tepid with nine holds and five sells against three intrepid buyers. The median price target is 378p, versus a current stock price of 395p – so is the outlook as dire as the market would suggest?

Idea B

Source: Thomson Reuters Eikon, StarMine

An ominous checklist

Let’s recap ICAP’s main challenges:

1. The changing regulatory environment for OTC trading.
2. Most revenue depends upon trading so the lowered volatility on many asset classes reduces activity.
3. Banks are a large part of the client base. According to a recent report by UBS, they still make up 80% of revenues and they’re hardly in great shape themselves.
4. EBS, ICAP’s FX platform, has been losing market share.

All of these challenges are well documented and understood in the marketplace, meaning any surprises are likely to be positive. The broader question is which challenges are structural and which are merely transitory or cyclical? While I am no expert on the regulatory environment, I think one can safely assume the greater transparency being forced on the OTC market to be structural, and the currently lowered volumes in many asset classes are likely cyclical.

Any time we hear forecasts of new realities and that we have tamed volatility, or the economic cycle, or other such nonsense, I always take note. How can anyone discount the likelihood of a macro shock, or of the consensus expectations in FX, bond and equity markets proving to be wrong?

Idea C

Source: Thomson Reuters Eikon, StarMine

Share price value

From a valuation perspective ICAP looks appealing. The current stock price is implying -2.7% growth each year for the next five, compared to a positive 4.9% expectation built into the broader investment banking /investment services sector. From a P/E standpoint, the company trades at 11.9 times forward earnings (the red line above), below its 10-year median of 12.4.

Idea D

Source: Thomson Reuters Eikon, StarMine

Dare and win?

The market is trading at all-time highs, with the U.K. market’s aggregated P/E ratio at 14.3. The VIX (measuring implied equity market volatility) is again approaching danger levels that show an overlay sanguine attitude to risk embedded in market participants. For those like me who don’t like a bullish consensus, here’s an interesting idea – a stock that actually will thrive in any kind of greater volatility as trading levels spike. Oh, and while you’re waiting around, there’s a 5.5% yield to help your carrying costs and the sellside doesn’t like the stock. For those with the risk profile: Qui audet adipiscitur (Who dares, wins).


Receive stories like this to your inbox as they are published. Subscribe here and follow us @Alpha_Now on Twitter or check out the Thomson Reuters Eikon blog. If you are looking to access Thomson Reuters data or analytics, register for a free trial.

We have updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.x